Head-and-neck Cancer Clinical Trial
Official title:
DAHANCA Proton Feasibility Study
A study to investigate feasibility of local selection of patients with squamous cell carcinoma of the pharynx or larynx using anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia.
In preparation for a randomised study in Denmark (DAHANCA 35) the feasibility of selecting newly diagnosed patients with squamous cell carcinoma of the pharynx or larynx for proton therapy at the local treatment centers is investigated. A proton and a photon doseplan is prepared for patients planned for primary radiotherapy . If proton radiotherapy reduces the anticipated absolute risk of dysphagia >= grade 2 (DAHANCA scale and/or xerostomia >= grade 2 (EORTC Head-Neck 35) with a clinical relevant value the patient is offered proton therapy at the Danish Center for Particle Therapy. The anticipated risk of xerostomia and dysphagia is estimated using Normal-Tissue Complication Models (NTCP). At least five patients from each of the six Danish centers are required in this feasibility study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04607694 -
DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer
|
N/A | |
Completed |
NCT02776137 -
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
|
Phase 2 | |
Recruiting |
NCT03552458 -
Effects of Probiotics in Preventing Oral Mucositis
|
Phase 2 | |
Recruiting |
NCT02238587 -
The Effect of Ganoderma on Patients With Head-and-neck Cancer
|
N/A | |
Enrolling by invitation |
NCT04257968 -
Long Term Complications in Head and Neck Cancer Patients
|
N/A | |
Recruiting |
NCT02764216 -
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
|
Phase 2 |